The clinical outcome of LT has improved significantly with refinements in surgical skill and immunosuppressive agents. Over the past decade, nationally most LT centers have improved their standard care in LT. As a result, short-term survival after LT has increased remarkably. However, recurrence of original liver disease, chronic rejection, and the adverse effect of immunosuppressive agents still impose significant limitations on long-term survival. Here at the MTI, it is our mission to continue technical innovation, improve the management of hepatitis C patients, search for better immunosuppressive protocols, and work towards achieving tolerance after LT to improve the long-term outcome.